Although their usefulness in clinical practice still needs to be confirmed, Gal-3 and sST2 have been included as biomarkers for myocardial fibrosis in the 2013 American College of Cardiology Foundation/American Heart Association (ACC/AHA) HF guidelines, for risk stratification as well as for prognosis in patients with moderate and severe HF (class IIb) [59]. Here, LGALS3 is linked to hydrops fetalis.